BeyondSpring Files 2024 Annual Report on Form 10-K
BeyondSpring (NASDAQ: BYSI), a global clinical-stage biopharmaceutical company focused on innovative cancer therapies, has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024. The report was submitted to the SEC on March 27, 2025.
The annual report, containing audited consolidated financial statements, is accessible through the SEC website and BeyondSpring's corporate website under the Investors section. The company offers shareholders the option to request free hard copies of the annual report through their Investor Relations department in Florham Park, NJ.
BeyondSpring (NASDAQ: BYSI), un'azienda biopharmaceutical globale in fase clinica focalizzata su terapie innovative per il cancro, ha presentato il suo rapporto annuale sul modulo 10-K per l'anno fiscale conclusosi il 31 dicembre 2024. Il rapporto è stato inviato alla SEC il 27 marzo 2025.
Il rapporto annuale, contenente bilanci consolidati auditati, è accessibile tramite il sito web della SEC e il sito web aziendale di BeyondSpring nella sezione Investitori. L'azienda offre agli azionisti la possibilità di richiedere copie cartacee gratuite del rapporto annuale attraverso il loro dipartimento Relazioni con gli Investitori a Florham Park, NJ.
BeyondSpring (NASDAQ: BYSI), una empresa biofarmacéutica global en etapa clínica centrada en terapias innovadoras contra el cáncer, ha presentado su informe anual en el Formulario 10-K para el año fiscal que terminó el 31 de diciembre de 2024. El informe fue enviado a la SEC el 27 de marzo de 2025.
El informe anual, que contiene estados financieros consolidados auditados, está accesible a través del sitio web de la SEC y el sitio web corporativo de BeyondSpring en la sección de Inversores. La empresa ofrece a los accionistas la opción de solicitar copias impresas gratuitas del informe anual a través de su departamento de Relaciones con Inversores en Florham Park, NJ.
비욘드스프링 (NASDAQ: BYSI), 혁신적인 암 치료에 중점을 둔 글로벌 임상 단계의 생물제약 회사가 2024년 12월 31일로 종료된 회계연도에 대한 10-K 양식 연례 보고서를 제출했습니다. 이 보고서는 2025년 3월 27일 SEC에 제출되었습니다.
감사된 통합 재무제표를 포함하는 연례 보고서는 SEC 웹사이트와 비욘드스프링의 기업 웹사이트 투자자 섹션을 통해 접근할 수 있습니다. 회사는 주주에게 플로럼 파크, NJ에 있는 투자자 관계 부서를 통해 연례 보고서의 무료 인쇄본을 요청할 수 있는 옵션을 제공합니다.
BeyondSpring (NASDAQ: BYSI), une entreprise biopharmaceutique mondiale en phase clinique axée sur des thérapies innovantes contre le cancer, a déposé son rapport annuel sur le formulaire 10-K pour l'exercice fiscal se terminant le 31 décembre 2024. Le rapport a été soumis à la SEC le 27 mars 2025.
Le rapport annuel, contenant des états financiers consolidés audités, est accessible via le site Web de la SEC et le site Web de BeyondSpring dans la section Investisseurs. L'entreprise offre aux actionnaires la possibilité de demander des copies papier gratuites du rapport annuel via leur département des Relations avec les Investisseurs à Florham Park, NJ.
BeyondSpring (NASDAQ: BYSI), ein globales biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf innovative Krebstherapien konzentriert, hat seinen Jahresbericht im Formular 10-K für das am 31. Dezember 2024 endende Geschäftsjahr eingereicht. Der Bericht wurde am 27. März 2025 bei der SEC eingereicht.
Der Jahresbericht, der geprüfte konsolidierte Finanzberichte enthält, ist über die Website der SEC und die Unternehmenswebsite von BeyondSpring im Bereich Investoren zugänglich. Das Unternehmen bietet den Aktionären die Möglichkeit, über die Abteilung Investor Relations in Florham Park, NJ, kostenlose gedruckte Kopien des Jahresberichts anzufordern.
- None.
- None.
FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”) on March 27, 2025. The annual report on Form 10-K, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.beyondspringpharma.com under “Financials & Filings” in the Investors section.
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 100 Campus Drive, Suite 410, Florham Park, NJ 07932 USA.
About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and a range of cancer indications. Plinabulin’s novel mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors to checkpoint inhibitors. Learn more at beyondspringpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet the Company’s expectations regarding the potential safety, the ultimate efficacy or clinical utility of the Company’s product candidates, increased competition in the market, the Company’s ability to meet Nasdaq’s continued listing requirements, and other risks described in BeyondSpring’s most recent Form 10-K on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Investor Contact: IR@beyondspringpharma.com
Media Contact: PR@beyondspringpharma.com
FAQ
When did BeyondSpring (BYSI) file its 2024 annual report?
Where can investors access BeyondSpring's (BYSI) 2024 annual report?
How can shareholders obtain a hard copy of BYSI's 2024 annual report?
What period does BeyondSpring's (BYSI) latest annual report cover?
